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Abstract Objective To describe the design, recruitment
and baseline characteristics of participants in a community
pharmacy based pharmacogenetic study of antihyperten-
sive drug treatment. Setting: Participants enrolled from the
population-based Pharmaco-Morbidity Record Linkage
System. Method We designed a nested case-control study
in which we will assess whether specific genetic poly-
morphisms modify the effect of antihypertensive drugs on
the risk of myocardial infarction. In this study, cases
(myocardial infarction) and controls were recruited through
community pharmacies that participate in PHARMO. The
PHARMO database comprises drug dispensing histories of
about 2,000,000 subjects from a representative sample of
Dutch community pharmacies linked to the national reg-
istrations of hospital discharges. Results In total we
selected 31010 patients (2777 cases and 28233 controls)
from the PHARMO database, of whom 15973 (1871 cases,
14102 controls) were approached through their community
pharmacy. Overall response rate was 36.3% (n = 5791,
794 cases, 4997 controls), whereas 32.1% (n = 5126, 701
cases, 4425 controls) gave informed consent to genotype
their DNA. As expected, several cardiovascular risk factors
such as smoking, body mass index, hypercholesterolemia,
and diabetes mellitus were more common in cases than in
controls. Conclusion Furthermore, cases more often used
beta-blockers and calcium-antagonists, whereas controls
more often used thiazide diuretics, ACE-inhibitors, and
angiotensin-II receptor blockers. We have demonstrated
that it is feasible to select patients from a coded database
for a pharmacogenetic study and to approach them through
community pharmacies, achieving reasonable response
rates and without violating privacy rules.
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Impact of findings on practice
• Pharmacogenetic research is important for clinical
practice because it will facilitate personalized medicine
in the (near) future.
• For antihypertensive drugs that are commonly used
conducting a clinical trial will lead to practical
constraints, therefore it is very important to perform
observational pharmacogenetic research.
• This study shows that it is feasible to perform patient
recruitment for this observational pharmacogenetic
research in community pharmacies in The Netherlands.
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• Pharmacists should play an important role in introduc-
ing pharmacogenetics into clinical practice; both in the
research and in the implementation phase.
Introduction
High blood pressure is a common and major risk factor for
cardiovascular disease, affecting approximately 25% of the
industrialized countries [1]. Despite the availability of a
variety of effective antihypertensive drugs, inadequate
control of blood pressure is common in hypertensive
patients, and responsible for a large proportion of the
burden of stroke and myocardial infarction (MI) in the
population [2, 3]. Although there are some weak predictors
of response to antihypertensive drugs, individualization of
treatment is mostly done empirically [4]. A better knowl-
edge of the mechanisms underlying individual variation in
the effectiveness of drugs may improve this situation.
Identification of genes which modify the response to anti-
hypertensive drugs provides the opportunity to optimize
safety and effectiveness of the currently available antihy-
pertensive drugs, and to design new drugs.
Studies of drug–gene interactions may be conducted
from a pharmacokinetic and a pharmacodynamic perspec-
tive [5, 6]. From a pharmacodynamic perspective, several
small studies have evaluated the influence of polymor-
phisms in renin-angiotensin system genes (angiotensin
converting enzyme (ACE), angiotensinogen (AGT),
angiotensin II type 1 receptor (AT1R)), the a-adducin gene,
and the b-adrenoceptor (bAR)-G protein system genes on
the response to antihypertensive drugs [7–11]. These
studies focused on blood pressure, arterial stiffness, or
regression of left ventricular hypertrophy as outcomes.
Although some suggested interactions between certain
genetic polymorphisms and antihypertensive therapy,
results were often inconsistent due to small sample sizes,
confounding factors, differences between populations,
focus on one single gene and failure to account for gene–
gene interactions [12]. These treatment–gene interactions
have not been evaluated extensively in large population-
based studies and the effects on clinically important out-
comes such as myocardial infarction are largely unknown.
Some studies in which genetic variation as determinant of
antihypertensive drug response was determined gave
inconsistent results [13–16]. Therefore it is important that
large population-based studies are performed to enable
comparing and possibly pooling of results and eventually
finding true drug–gene interactions.
We designed a nested case-control study in which we
will assess whether specific genetic polymorphisms modify
the effect of antihypertensive drugs on the risk of myo-
cardial infarction. In our study the objective is to assess
interactions between antihypertensive drugs (notably
diuretics, ACE-inhibitors, b-blockers and calcium antago-
nists) and genetic polymorphisms (e.g. AGT, a-adducin,
Gp-b3, ACE, AT1R, G-a protein, b-2 and b-1 adrenergic
receptors, epithelial sodium channel (EnaC), cytochrome
P-450 enzymes (CYP2D6, CYP2C9, CYP3A4), and
P-glycoprotein) with respect to cardiovascular outcomes.
In this study, subjects were recruited through community
pharmacies. This paper describes the design and imple-
mentation of the study, and shows the baseline
characteristics of subjects who participate in the study.
Methods
Design and setting
A nested case-control design was used to assess whether
specific genetic polymorphisms modify the effect of anti-
hypertensive drugs on the risk of myocardial infarction.
Participants were enrolled from the population-based
Pharmaco-Morbidity Record Linkage System (PHARMO).
PHARMO links drug dispensing histories from a repre-
sentative sample of Dutch community pharmacies to the
national registrations of hospital discharges (LMR) from
1985 onwards. Currently, the base population of PHARMO
covers about 2,000,000 community-dwelling inhabitants of
several population-defined areas in The Netherlands, a
sample comparable to the general Dutch population.
Approval for this study was obtained from the Medical
Ethics Committee of the University Medical Center Utr-
echt, The Netherlands.
Case and control definition
In the PHARMO database subjects who used antihyper-
tensive drugs (low-ceiling diuretics, b-blockers, ACE-
inhibitors, calcium antagonists, angiotensin-II type 1
receptor blockers (ARB), miscellaneous antihypertensives
and combinations of antihypertensives) were selected.
From this cohort, subjects hospitalised for MI (ICD-9 code
410) were included as cases if they had at least one pre-
scription for antihypertensive drugs in the 3 months prior
to their first MI hospitalisation and were registered in
PHARMO for at least 1 year. The index date was defined
as the date of admission for the first myocardial infarction.
Patients were excluded if they were\18 years of age, if the
last prescription was not more than 100 days before index
date (90 days plus 10 days to account for irregularity of
refills), if they had had a previous MI, or if the date of birth
and sex filled in the questionnaire did not match the data in
the PHARMO database. Initially we randomly selected six
control subjects for each case from the subset of
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antihypertensive drug users, assuming a 50% response rate.
All non-responders were contacted by telephone. However,
because the response rate was lower than expected and
because the effort to include a sufficient number of controls
per case was substantial, the number of controls we selected
for each case was later increased to 12 and non-responsive
controls were not contacted anymore. Controls met the
same eligibility criteria as the cases, but did not have an MI.
They were matched to the cases on age (±1 year), sex and
area of residence and were assigned the same index date as
the case to whom they had been matched.
Patient recruitment
From the PHARMO institute a list with patient identifying
numbers which were linked to patient research numbers
was available. Subjects were recruited through community
pharmacies, which participate in PHARMO. From the
participating pharmacy the subjects received a letter in
which the purpose of the study was explained. They were
asked to return an informed consent form and a question-
naire to the PHARMO institute. The informed consent
form contains name, birth date and patient identifying
number and is stored separately at the PHARMO institute.
The questionnaire contains the patient research number.
After the participant had consented to participate in the
study (s)he was sent a package with three tubes with the
patient research number and three cotton swabs for a
buccal swab procedure. All participants were explicitly
asked to consent for the collection, storage and genotyping
of the buccal swab material. All patients were notified that
we used information from general practitioners through
anonymous linkage with the pharmacy data.
Ascertainment of exposure to antihypertensive drugs
Coded pharmacy records were used to ascertain exposure
to antihypertensive drugs. In PHARMO, complete phar-
macy records are available as of 1991. Pharmacy records
provide details on day of delivery, daily dose, and dura-
tions of therapy. We distinguished major antihypertensive
drug classes such as low-ceiling diuretics, b-blockers,
ACE-inhibitors, calcium antagonists, angiotensin-II type 1
receptor blockers (ARB), miscellaneous antihypertensives
and combinations of antihypertensives. Compliance was
judged from the regularity of refills.
Assessment of potential confounding factors
and effect-modifiers
In our study we have collected information on smoking,
hypertension, hypercholesterolemia, diabetes mellitus, use
of alcohol, diets, history of cardiovascular diseases, family
history of cardiovascular diseases, weight and height
through self-administered questionnaires. For a part of the
population information from automated general practice
and laboratory registrations is available. For all partici-
pants, information about risk factors was assessed before
the index date.
Buccal cell collection and DNA extraction
Individuals who agreed to participate in the study were
asked to supply a sample of buccal cells, collected by the
participants themselves. They received one page of col-
lection instructions, three cotton swabs, three 15 ml tubes
containing 2 ml buffer (1880 ll STE (100 mM NaCl,
10 mM EDTA, 10 mM Tris), 100 ll 10% SDS and 20 ll
of 10 mg/ml Proteinase K).
Genotyping
Genotypes of the a-adducin, ACE, angiotensinogen,
angiotensin II type 1 receptor, eNOS and G-protein-b3,
polymorphisms were assessed using a multiplex single base
extension (SBE) method. Multiplex SBE was performed
using SNaPshotTM as described by the manufacturer
(Applied Biosystems). This method was described earlier
but adapted to this new set of polymorphisms. Laboratory
personnel were blinded both to case-control status and to
antihypertensive drug-therapy. Briefly, this assay uses
pooled PCR primer pairs to co-amplify 27 targets from
genomic DNA in two reactions. Amplified fragments
within each PCR products pool are then detected colori-
metrically with sequence-specific oligonucleotide probes
immobilized in a linear array on nylon membranes [17].
Table 1 shows an overview of the polymorphisms geno-
typed in the PHARMO-study linked to the antihypertensive
drug class that might be influenced by this polymorphisms.
This selection was made based on literature search and the
knowledge of the action mechanism of the drugs.
Analysis
Conditional logistic regression analysis will be used to
study the association between antihypertensive drug use
and the incidence of myocardial infarction and to adjust for
potential confounding. All analyses will be stratified by the
genetic polymorphisms to study effect modification.
Analyses will also be stratified by antihypertensive drug
class. Stratified analysis will also be used to account for
gene–gene interactions. Interaction terms (drug 9 geno-
type) will be included in the logistic regression model to
calculate synergy indices (SI). We will test genotype-
effect, dominant and recessive models, and allele-effect
associations.
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Results
In total 31,010 patients (2,777 cases and 28,233 controls)
were selected from the PHARMO-database, of whom
15,973 were approached by their pharmacies. The other
15,037 patients could not be approached for different
reasons (for example they died or moved or for controls
the case to whom they were matched did not participate).
In total 5,791 patients responded by filling in the ques-
tionnaire, which gave an overall response rate of 36.3%,
and 5,126 (31.7%) gave informed consent to genotype
their DNA. Baseline characteristics from the 794 cases
and 4,997 controls are shown in Table 2. As expected the
determinants smoking, body mass index, hypercholester-
olemia, and diabetes mellitus were different between
cases and controls. Furthermore, beta-blockers and cal-
cium-antagonists were used more often by cases than
controls, whereas thiazide diuretics, ACE-inhibitors and
angiotensin-II blockers were used more often by controls
than cases. Ethnicity did not differ between cases and
controls and because of the matching neither did age nor
did gender.
Discussion
The recently completed sequencing of the human genome
has focused attention on the potential for genetic infor-
mation to benefit the diagnosis, evaluation and treatment of
common diseases. Pharmacogenetics is a research field that
pursues the identification and characterization of genes that
influence individual responses to drug treatment. The
availability of more and more data on the existence of
genes and their variability, will give rise to an increase in
pharmacogenetic research. In the field of hypertension, an
important goal is to ascertain which of the genes influence
the effects of antihypertensive drugs on blood pressure,
assess the extent and impact of their polymorphisms and
distinguish which pathways are valid targets for interven-
tion. Although the public health importance of the results
of pharmacogenetic studies may be considerable, reliable
information is still limited in this area and needs to be
assessed.
We have designed a nested case-control study in which
we will assess whether genetic polymorphisms modify the
effect of antihypertensive drugs on the risk of MI. In our
Table 1 Summary of the polymorphisms genotyped in the PHARMO study that might influence antihypertensive drug therapy by drug class
Drug Polymorphism
(nucleotide substitution)
Amino Acid substitution (3-coded; 1-coded) dbSNP
rs number
Thiazide diuretics ADD1 G460T Glycine–Trytophane (gly–trp; G–W) 4961
AGT C235T Methionine–Threonine (met–thr; M–T) 699
ACE G4656C Non-coding 4341
ACE T3892C Non-coding 1800764
AGTR1 A1166C Non-coding 5186
GNB3 C825T No substitution (Serine–Serine; ser; S) 5443
NOS3 G298T Aspartic Acid–Glutamic Acid (Asp–Glu; D–E) 1799983
Beta-blocker AGT C235T Methionine–Threonine (met–thr; M–T) 699
ACE G4656C Non-coding 4341
ACE T3892C Non-coding 1800764
AGTR1 A1166C Non-coding 5186
GNB3 C825T No substitution (Serine–Serine; ser; S) 5443
ACE-inhibitor AGT C235T Methionine–Threonine (met–thr; M–T) 699
ACE G4656C Non-coding 4341
ACE T3892C Non-coding 1800764
AGTR1 A1166C Non-coding 5186
AT1R antagonist AGT C235T Methionine–Threonine (met–thr; M–T) 699
ACE G4656C Non-coding 4341
ACE T3892C Non-coding 1800764
AGTR1 A1166C Non-coding 5186
Calcium channel blocker AGT C235T Methionine–Threonine (met–thr; M–T) 699
ACE G4656C Non-coding 4341
ACE T3892C Non-coding 1800764
AGTR1 A1166C Non-coding 5186
NOS3 G298T Aspartic Acid–Glutamic Acid (Asp–Glu; D–E) 1799983
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study we have access to data on all different antihyper-
tensive drugs and therefore include different calcium
channel blockers, ACE inhibitors, alpha-adrenergic block-
ers and diuretics. Furthermore, in our study data is also
available on the use of b-blockers.
A limitation of our study is the use of self-reported data.
However, in about 40% of the PHARMO population,
computerized general practice and clinical laboratory data
are available. This will allow us to conduct several sensi-
tivity analyses and validation studies. Another limitation is
Table 2 Baseline
characteristics of the
participants
Cases (n = 794)
Number (%)
Controls (4997)
Number (%)
P-value
Age in years (SD) 64.8 (10.8) 64.5 (10.3)
Female 261 (32.9) 1,639 (32.8)
Consent DNA 701 (88.3) 4,427 (88.6)
DNA available 631 (79.5) 3,952 (79.1)
Antihypertensive drugs
Thiazide diuretics 131 (16.8) 1,204 (24.5) \0.0005
Beta blockers 362 (46.4) 2,344 (47.8) 0.48
ACE-inhibitors 173 (22.2) 1,539 (31.4) \0.0005
Ca-antagonists 232 (29.7) 1,061 (21.6) \0.0005
AT2-antagonists 66 (8.5) 682 (13.9) \0.0005
Alpha-blockers 10 (1.3) 69 (1.4) 0.78
Combination 65 (8.3) 627 (12.8) \0.0005
Smoking N = 720 N = 4,597
Never 226 (31.4) 1,769 (38.5) \0.0005
Current 154 (21.4) 695 (15.1)
Past 340 (47.2) 2,133 (46.4)
BMI N = 688 N = 4,200
[30 kg/m2 164 (23.8) 849 (20.2) 0.03
Hypercholesterolemia N = 757 N = 4,810
No 258 (34.1) 2,438 (50.7) \0.0005
Yes, no drug treatment 306 (40.4) 918 (19.1)
Yes, drug treatment 193 (25.5) 1,454 (30.2)
Diabetes mellitus N = 766 N = 4,845
No 593 (77.4) 3,914 (80.8) 0.02
Yes, no drug treatment 80 (10.4) 367 (7.6)
Yes, drug treatment 93 (12.1) 564 (11.6)
Physical activity N = 776 N = 4,881
\4 h 238 (30.7) 1,303 (26.7) 0.02
C4 h 538 (69.3) 3,578 (73.3)
Alcohol use N = 761 N = 4790
no use 173 (22.7) 966 (20.2) 0.02
\1 per day 192 (25.3) 1,194 (24.9)
1–2 per day 41 (5.4) 360 (7.5)
[2 per day 25 (3.3) 258 (5.4)
yes (unknown quantity) 330 (43.4) 2,012 (42.0)
Family history MI N = 780 N = 4903
No 724 (92.8) 4,642 (94.7) 0.08
Yes \ 60 years 6 (0.8) 20 (0.4)
Yes [ 60 years 50 (6.4) 241 (4.9)
Ethnicity N = 776 N = 4,868
Caucasian 759 (97.8) 4,746 (97.5) 0.75
Other 17 (2.2) 122 (2.5)
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the use of computerized pharmacy data. The pharmacy
records measured prescriptions filled rather than drugs
taken. Moreover antihypertensive drug users with fatal MI
were not selected for the study because they were not
registered in the PHARMO database.
A number of studies have investigated genetic poly-
morphisms as determinants of cardiovascular response to
antihypertensive drug therapy. They used different study
designs such as experimental (e.g. randomized clinical
trial) and observational (e.g. cohort and case-control)
studies. Data from randomized controlled trials constitute
the highest order of evidence and remain the standard for
comparisons between therapies [18]. However, randomized
controlled trials may not always feasible due to practical,
financial or ethical reasons. Many clinical trials that are
performed now are saving blood specimens, but most
earlier trials do not have blood samples available. Obser-
vational studies are the main alternatives [19]. Moreover
observational studies represent a more accurate accounting
of everyday clinical care and estimates of treatment effects
are more generalisable to the general population. In
observational studies factors that determined whether a
patient received a specific drug or not could result in dif-
ference between groups in prognostics factors related to the
outcome. Specific patient characteristics, clinical judgment
and consideration of the best option for the patient will
influence the decision of the treating physician to prescribe
a specific antihypertensive drug. For instance hypertensive
patients with diabetes mellitus are more likely to receive
ACE-inhibitors. However in observational pharmacoge-
netic studies drug–gene interactions are probably not
influenced by these problems, as the prescriber is unaware
of a patient’s genotype. Information from both randomized
controlled trials and outcomes databases is necessary to
determine appropriate treatment for individual patients.
The unique and new feature about our study is the
enrollment of the subjects. All subjects were approached
through the community pharmacies which participate in
PHARMO. The enforcement of this population based study
is therefore relatively easy and the threshold to participate
is kept as low as possible.
Conclusion
This study demonstrates the feasibility of setting up a ret-
rospective study by collecting information through
community pharmacies and patients themselves.
The results of this study will help to assess the clinical
relevance of antihypertensive drug–gene interactions.
Understanding the association between antihypertensive
drug–gene interactions and various cardiovascular out-
comes may eventually help physicians and other health
professionals to tailor antihypertensive drug therapy to the
individual patient.
Acknowledgements The authors would like to thank the following
for their support during the project implementation: Karin J.A.
Lievers at University of Utrecht, P. Schiffers and R.J. Janssen at
University of Maastricht, Cornelia M. van Duijn at Erasmus Medical
Centre Rotterdam, Bruce M. Psaty at University of Washington and
W.M. Monique Verschuren at National Institute of Public Health and
the Environment Bilthoven.
Funding This study is funded by grant no. 2001.064 of The Neth-
erlands Heart Foundation. A.H. Maitland-van der Zee is funded by a
Veni grant from the Netherlands Organization for Scientific Research
(NWO)
Conflicts of Interest The department employing authors BMAW,
AHM, OHK, AB receives unrestricted research grants for pharma-
coepidemiological research from the private-public funded Top
Institute Pharma (includes co-funding from universities, government,
and industry—GSK, Organon, Merck) and GSK. The authors AB and
OHK received an unrestricted research grant for pharmacoepidemi-
ological research on diabetes mellitus.
The experiments in this study comply with the current laws in The
Netherlands. Approval for this study was obtained from the Medical
Ethics Committee of the University Medical Center Utrecht, The
Netherlands.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
Reference
1. Mosterd A, D’Agostino RB, Silbershatz H, Sytkowski PA,
Kannel WB, Grobbee DE, et al. Trends in the prevalence of
hypertension, antihypertensive therapy, and left ventricular
hypertrophy from 1950 to 1989. N Engl J Med. 1999;340:1221–7.
doi:10.1056/NEJM199904223401601.
2. Klungel OH, Stricker BH, Paes AH, Seidell JC, Bakker A, Voko
Z, et al. Excess stroke among hypertensive men and women
attributable to undertreatment of hypertension. Stroke. 1999;30:
1312–8.
3. Kaplan RC, Psaty BM, Heckbert SR, Smith NL, Lemaitre RN.
Blood pressure level and incidence of myocardial infarction
among patients treated for hypertension. Am J Public Health.
1999;89:1414–7.
4. Weder AB. Selecting the right drug for initial antihypertensive
therapy. Curr Hypertens Rep. 2000;2:13–5. doi:10.1007/s11906-
000-0052-9.
5. Evans WE, Relling MV. Pharmacogenomics: translating func-
tional genomics into rational therapeutics. Science.
1999;286:487–91. doi:10.1126/science.286.5439.487.
6. Maitland-van der Zee AH, de Boer A, Leufkens HG. The inter-
face between pharmacoepidemiology and pharmacogenetics. Eur
J Pharmacol. 2000;410:121–30. doi:10.1016/S0014-2999(00)
00810-4.
7. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M,
et al. Polymorphisms of alpha-adducin and salt sensitivity in
patients with essential hypertension. Lancet. 1997;349:1353–7.
doi:10.1016/S0140-6736(97)01029-5.
Pharm World Sci (2009) 31:158–164 163
123
8. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE,
Brown MJ. Renin-angiotensin system gene polymorphisms
influence blood pressure and the response to angiotensin con-
verting enzyme inhibition. J Hypertens. 1995;13:1602–9.
9. Benetos A, Cambien F, Gautier S, Ricard S, Safar M, Laurent S,
et al. Influence of the angiotensin II type 1 receptor gene poly-
morphism on the effects of perindopril and nitrendipine on
arterial stiffness in hypertensive individuals. Hypertension.
1996;28:1081–4.
10. Jia H, Hingorani AD, Sharma P, Hopper R, Dickerson C,
Trutwein D, et al. Association of the G(s)alpha gene with
essential hypertension and response to beta-blockade. Hyperten-
sion. 1999;34:8–14.
11. Kohno M, Yokokawa K, Minami M, Kano H, Yasunari K,
Hanehira T, et al. Association between angiotensin-converting
enzyme gene polymorphisms and regression of left ventricular
hypertrophy in patients treated with angiotensin-converting
enzyme inhibitors. Am J Med. 1999;106:544–9. doi:10.1016/
S0002-9343(99)00067-4.
12. Williams SM, Addy JH, Phillips JAIII, Dai M, Kpodonu J, Afful
J, et al. Combinations of variations in multiple genes are asso-
ciated with hypertension. Hypertension. 2000;36:2–6.
13. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-
Foster C, Miller MB, et al. Pharmacogenetic association of the
angiotensin-converting enzyme insertion/deletion polymorphism
on blood pressure and cardiovascular risk in relation to antihy-
pertensive treatment: the Genetics of Hypertension-Associated
Treatment (GenHAT) study. Circulation. 2005;111:3374–83. doi:
10.1161/CIRCULATIONAHA.104.504639.
14. Davis BR, Arnett DK, Boerwinkle E, Ford CE, Leiendecker-
Foster C, Miller MB, et al. Antihypertensive therapy, the alpha-
adducin polymorphism, and cardiovascular disease in high-risk
hypertensive persons: the Genetics of Hypertension-Associated
Treatment Study. Pharmacogenomics J. 2007;7:112–22. doi:
10.1038/sj.tpj.6500395.
15. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN,
Reiner AP, et al. Diuretic therapy, the alpha-adducin gene vari-
ant, and the risk of myocardial infarction or stroke in persons with
treated hypertension. JAMA. 2002;287:1680–9. doi:10.1001/
jama.287.13.1680.
16. Bis JC, Smith NL, Psaty BM, Heckbert SR, Edwards KL,
Lemaitre RN, et al. Angiotensinogen Met235Thr polymorphism,
angiotensin-converting enzyme inhibitor therapy, and the risk of
nonfatal stroke or myocardial infarction in hypertensive patients.
Am J Hypertens. 2003;16:1011–7. doi:10.1016/j.amjhyper.2003.
07.018.
17. Knaapen AM, Ketelslegers HB, Gottschalk RW, Janssen RG,
Paulussen AD, Smeets HJ, et al. Simultaneous genotyping of nine
polymorphisms in xenobiotic-metabolizing enzymes by multiplex
PCR amplification and single base extension. Clin Chem.
2004;50:1664–8. doi:10.1373/clinchem.2004.034058.
18. Mack MJ. Clinical trials versus registries in coronary revascu-
larization: which are more relevant? Curr Opin Cardiol. 2007;22:
524–8.
19. Klungel OH, Martens EP, Psaty BM, Grobbee DE, Sullivan SD,
Stricker BH, et al. Methods to assess intended effects of drug
treatment in observational studies are reviewed. J Clin Epidemiol.
2004;57:1223–31. doi:10.1016/j.jclinepi.2004.03.011.
164 Pharm World Sci (2009) 31:158–164
123
